Daily Stock Analysis, ACOR, Acorda Therapeutics Inc, priceseries

Acorda Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
25.45
Close
25.40
High
25.60
Low
25.10
Previous Close
25.40
Daily Price Gain
0.00
YTD High
33.00
YTD High Date
Mar 9, 2017
YTD Low
18.85
YTD Low Date
Jan 3, 2017
YTD Price Change
5.90
YTD Gain
30.26%
52 Week High
33.00
52 Week High Date
Mar 9, 2017
52 Week Low
16.40
52 Week Low Date
Nov 3, 2016
52 Week Price Change
0.02
52 Week Gain
0.08%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 11. 2015
31.03
Jun 26. 2015
33.36
11 Trading Days
7.50%
Link
LONG
Oct 21. 2015
31.71
Nov 13. 2015
37.03
17 Trading Days
16.78%
Link
LONG
Dec 15. 2015
38.47
Jan 4. 2016
41.63
12 Trading Days
8.22%
Link
LONG
Jan 3. 2017
19.50
Jan 17. 2017
20.66
9 Trading Days
5.95%
Link
LONG
Feb 14. 2017
23.85
Mar 14. 2017
27.73
19 Trading Days
16.27%
Link
Company Information
Stock Symbol
ACOR
Exchange
NasdaqGS
Company URL
http://www.acorda.com
Company Phone
914-347-4300
CEO
Ronald Cohen
Headquarters
New York
Business Address
420 SAW MILL RIVER ROAD, ARDSLEY, NY 10502
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001008848
About

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States.

Description

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that is in the Phase IIb clinical trial for the treatment of OFF periods in Parkinson's disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; and Ampyra/Dalfampridine that is in the Phase I pharmacokinetic studies for the treatment of chronic post-stroke deficits. Further, it develops Plumiaz, a proprietary nasal spray formulation of diazepam to treat people with epilepsy; Cimaglermin alfa/Neuregulins that has completed a Phase I clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase I clinical trial for the treatment of MS; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.